| Nov 20, 2009 | 06:50 | Trading Review for Vivus Inc. Issued by Beacon Equity |
| BeaconEquity.com announces an investment report featuring biopharmaceutical company Vivus Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
continued... |
|
| Nov 19, 2009 | 06:50 | Trading Overview for Sinobiopharma Inc. Issued by StockPreacher.com |
| StockPreacher.com announces an investment report featuring biotechnology company Sinobiopharma Inc. (OTCBB:SNBP). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
continued... |
|
| Nov 18, 2009 | 08:00 | Initial Phase 2 Results for Myriad Pharmaceuticals' Azixa(TM) (MPC-6827) in Metastatic Melanoma |
 | Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of initial clinical data from an ongoing Phase 2a study of Azixa(TM) (MPC-6827), a microtubule destabilizing agent in stage 4 melanoma patients. Azixa is in two additional phase 2 studies in recurrent glioblastoma multiforme (GBM). Myriad Pharmaceuticals further announces that it has received orphan drug status for Azixa in GBM.
continued... |
|
| Nov 18, 2009 | 06:50 | Trading Review for Cerus Corp. Issued by Beacon Equity |
| BeaconEquity.com announces an investment report featuring Cerus Corp. (Nasdaq:CERS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
continued... |
|
| Nov 18, 2009 | 06:50 | StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc. |
| StockPreacher.com announces an investment report featuring biopharmaceutical company Arena Pharmaceuticals Inc. (Nasdaq:ARNA). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
continued... |
|
| Nov 18, 2009 | 02:05 | Evotec Wins German Government Research Grant |
| Evotec (Frankfurt:EVT) (TecDAX), a leading provider in the discovery and development of novel small molecule drugs, today announced that it has been granted up to EUR 2.5 m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase for potential use in neuroprotection. Evotec will use its drug discovery platform and expertise in progressing this program towards the clinic, particularly making use of its high quality compound library and proprietary fragment-based drug discovery platform.
continued... |
|
| Nov 17, 2009 | 12:30 | OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference |
 | OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported positive interim safety data from the FALCON (Fosbretabulin in Advanced Lung Oncology) study, a Phase 2, randomized, controlled study of ZYBRESTAT (fosbretabulin) in patients with advanced non-small cell lung cancer (NSCLC). The data from this planned interim safety analysis indicated that the combination of fosbretabulin with carboplatin and paclitaxel plus bevacizumab (Avastin(R)) appeared to be well-tolerated, and that there were no significant overlapping toxicities with bevacizumab. Notably, 5 of the 6 patient deaths during the evaluation period were due to disease progression and occurred in the control arm. The data were presented in a poster by Edward Garon, M.D., Assistant Professor of Medicine at the University of California, Los Angeles, principal investigator for the Phase 2 trial, at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference. A further analysis of the efficacy and tolerability of this novel combination is expected to be presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO), scheduled for June 4-8, 2010 in Chicago, IL.
continued... |
|
| Nov 17, 2009 | 11:03 | Health Enhancement Products, Inc. 10Q Available for Review at www.sec.gov |
| Health Enhancement Products, Inc. (OTCBB:HEPI) today announced that its Quarterly Report on Form 10Q for the quarter ended September 30, 2009 was inadvertently filed by its EDGAR filing Agent under HEPI Pharmaceuticals, Inc., the Company's wholly owned subsidiary. Accordingly, the Company's Form 10Q can be viewed at www.sec.gov under the issuer name "HEPI Pharmaceuticals, Inc." The Company is taking steps to rectify this filing error.
continued... |
|
| Nov 17, 2009 | 10:43 | Neptune Technologies & Bioressources Inc. Reports on Medical Food Candidate Preclinical Research; Pilot ADHD Effect is Confirmed |
| Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX-V:NTB) announced today the first preclinical research up-date on NeuroBioPharm Inc. ("NBP") medical food development program.
continued... |
|
| Nov 17, 2009 | 08:00 | Infinity's IPI-504 Named One of Windhover and Campbell Alliance's "Top 10 Projects to Watch" in Oncology |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Jeffrey Tong, Ph.D., vice president, corporate and product development, will present an overview of IPI-504 (retaspimycin hydrochloride), the company's intravenous heat shock protein 90 (Hsp90) chaperone inhibitor, at the Therapeutic Area Partnerships event tomorrow, November 18, 2009 at 3:30 p.m. EST. The conference, being held November 17-19, in Boston, showcases Windhover and Campbell Alliance's 2009 "Top 10 Projects to Watch" and partnership opportunities in oncology.
continued... |
|
| Nov 17, 2009 | 08:00 | XOMA Appoints Jim Neal Vice President of Business Development |
 | XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that James R. Neal has joined the company as Vice President, Business Development. Mr. Neal will oversee XOMA's business development strategy and lead the team to execute key licensing initiatives to build and support XOMA's proprietary therapeutic pipeline and biodefense programs, to market the company's antibody technologies and to assess commercial opportunities and develop product candidates commercially.
continued... |
|
| Nov 17, 2009 | 07:00 | Discovery Labs Submits SURFAXIN Pharmacodynamic Trial Protocol to FDA |
 | Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that it has submitted to the U.S. Food and Drug Administration (FDA) its proposed protocol for a Surfaxin(R) (lucinactant) limited clinical trial. The protocol incorporates a clinical trial design that is primarily intended to assess a pharmacodynamic (PD) response following Surfaxin administration in preterm infants with Respiratory Distress Syndrome (RDS). Discovery Labs proposed this trial design in response to a comment by the FDA that a limited clinical trial could potentially resolve the key remaining issue for approval of Surfaxin for the prevention of RDS in premature infants.
continued... |
|
| Nov 17, 2009 | 07:00 | Cyclacel Pharmaceuticals to Present Sapacitabine Phase 2 AML & MDS Data at the Upcoming American Society of Hematology Meeting |
| Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of advanced myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at two poster presentations during the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA, on Saturday, December 5, 2009.
continued... |
|
| Nov 17, 2009 | 06:50 | Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity |
| BeaconEquity.com announces an investment report featuring Poniard Pharmaceuticals Inc. (Nasdaq:PARD). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
continued... |
|
| Nov 16, 2009 | 09:30 | Adelene Q. Perkins Named "Best Executive" at Annual Stevie(R) Awards Ceremony |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Adelene Q. Perkins, president and chief business officer, was named the 2009 "Best Executive: Non-Services Business" in the 6th Annual Stevie Awards for Women in Business, presented at the Annual Award Dinner and Ceremony held on November 13, 2009 in New York City.
continued... |
|
| More >>
